• Marissa Howard-McNatt, Julia Lawrence, Susan A Melin, Edward A Levine, Perry Shen, and John H Stewart.
• Department of Surgical Oncology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. mmcnatt@wakehealth.edu
• Am. J. Surg. 2013 Apr 1;205(4):397-401.

BackgroundBlack women can have worse outcomes than white women with breast cancer. We examined survival in black and white women who received neoadjuvant chemotherapy.MethodsWe identified 98 women with stage II or III breast cancer who underwent neoadjuvant chemotherapy. Women with inflammatory breast cancer, T4 disease, or metastases were excluded. Data were analyzed using the Fisher exact test and Kaplan-Meier method.ResultsFrom the cohort, 69 women were included. The median follow-up was 6.2 years. The estrogen receptor status was similar. White women tended to overexpress human epidermal growth factor receptor 2 (HER2) (P = .091). The pretreatment T stage was T3. All women received similar neoadjuvant chemotherapy. The 5-year progression-free survival was better for white women compared with black women (78% vs 58%, P = .05). The 5-year overall survival was similar (P = .095).ConclusionsThe pretreatment characteristics of women receiving neoadjuvant chemotherapy were similar. Black women had a worse disease-free survival. The overall survival was the same.Copyright © 2013 Elsevier Inc. All rights reserved.

38 keywords...

hide…